Skip to main content

Advertisement

SpringerLink
Log in

Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Purpose

Kampo medicine Hangeshashin-to (TJ-14) which contains baicalin, a β-glucuronidase inhibitor, alleviates diarrhea induced by irinotecan (CPT-11). We conducted a randomized comparative trial to investigate whether support with TJ-14 would prevent and control CPT-11-induced diarrhea.

Methods

Of 44 previously untreated patients with advanced non-small-cell lung cancer randomized, 41 (18 TJ-14 group, 23 control group) were available for evaluation. The chemotherapy regimen consisted of a combination of cisplatin and CPT-11. TJ-14 (7.5 g/day) was administered orally.

Results

Of the 41 patients, 39 experienced diarrhea. Compared with the control group, the TJ-14 group showed a significant improvement in diarrhea grades (P=0.044) as well as a reduced frequency of diarrhea grades 3 and 4 (one patient versus ten patients; P=0.018). However, the two groups showed no differences in the frequency of diarrhea or the number of days the symptoms continued. This study was stopped at an interim evaluation.

Conclusion

TJ-14 was effective in preventing and controlling CPT-11-induced diarrhea.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abigerges D, Armand J-P, Chabot GG, Costa LD, Fadel E, Cote C, Herait D, Gandia D (1994) Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86:446

    CAS  PubMed  Google Scholar 

  2. Asumi R, Suzuki W, Hakusui H (1991) Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 21:1159

    PubMed  Google Scholar 

  3. Fukuoka M, Masuda N, Furuse K, Negoro S, Takada M, Matsui K, Takifuji N, Kudoh S, Kawahara M, Ogawara M, Kodama N, Kubota K, Yamamoto M, Kusunoki Y (1991) A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. J Clin Oncol 9:606

    CAS  PubMed  Google Scholar 

  4. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T (1992) A phase II study of CPT-11, a new derivative of untreated non-small-cell lung cancer. J Clin Oncol 10:16

    CAS  PubMed  Google Scholar 

  5. Gandia D, Abigerges D, Armand J-P, Chabot G, Costa LD, Forni MD (1993) CPT-11 induced cholinergic effects in cancer patients (letter). J Clin Oncol 11:196

    CAS  PubMed  Google Scholar 

  6. Kaneda N, Nagata H, Furuta T, Yokokura T (1990) Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in mouse. Cancer Res 50:1715

    PubMed  Google Scholar 

  7. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M (1987) Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin, a novel water soluble derivative of camptothecin, against murine tumors. Cancer Res 47:5944

    CAS  PubMed  Google Scholar 

  8. Masuda N, Fukuoka M, Kusunoki Y, Mastui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takada M (1992) CPT-11: a new derivative of camptothecin, for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225

    CAS  PubMed  Google Scholar 

  9. Matsuzaki T, Yokokura T, Mutai M, Tsuruo T (1988) Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 21:308

    CAS  PubMed  Google Scholar 

  10. Mori K, Saito Y, Tominaga K (1992) Phase II study of cisplatin continuous infusion plus vindesine in the treatment of non-small-cell lung cancer. Am J Clin Oncol 15:344

    CAS  PubMed  Google Scholar 

  11. Mori K, Hirose T, Machida S, Yokoyama K, Tominaga K (1997) A phase I study of irinotecan and infusional cisplatin with recombinant human granulocyte colony-stimulating factor support in the treatment of advanced non-small cell lung cancer. Eur J Cancer 33:503

    Article  CAS  PubMed  Google Scholar 

  12. Narita M, Nagai E, Hagiwara H, Aburada M, Yokoi T, Kamataki T (1993) Inhibition of β-glucuronidase by natural glucuronides of Kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. Xenobiotica 23:5

    CAS  PubMed  Google Scholar 

  13. Negoro S, Fukuoka N, Masuda N, Takada M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Niitani H, Taguchi T (1991) Phase I study of weekly administration of CPT-11. J Natl Cancer Inst 83:1164

    CAS  PubMed  Google Scholar 

  14. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346:85

    Article  CAS  PubMed  Google Scholar 

  15. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, Ariyoshi H, Ichimaru M, Sakai Y, Oguro M, Ito Y, Morishima Y, Yokomaku S, Ota K (1990) An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8:1907

    CAS  PubMed  Google Scholar 

  16. Oshita F, Noda K, Nishiwaki Y, Fujita A, Kurita Y, Nakabayashi T, Tobise K, Abe S, Suzuki S, Hayashi I, Kawakami Y, Matsuda T, Tsuchiya S, Takahashi S, Tamura T, Saijo N (1997) Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer. J Clin Oncol 15:304

    CAS  PubMed  Google Scholar 

  17. Rothenberg ML, Kuhn JG, Burris HA III, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez Gl, Rock MK, Von Hoff DD (1993) Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194

    CAS  PubMed  Google Scholar 

  18. Sakata Y, Suzuki H, Kamataki T (1994) Preventive effect of TJ-14, a Kampo (Chinese herb) medicine, on diarrhea induced by irinotecan hydrochloride (CPT-11) (in Japanese with English abstract). Jpn J Cancer Chemother 21:1241

    CAS  Google Scholar 

  19. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N (1993) Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11:909

    CAS  PubMed  Google Scholar 

  20. Takasuna K, Kasai Y, Kitano Y, Mori K, Kobayashi R, Hagiwara T, Kakihata K, Hirohashi M, Nomura M, Nagai E, Kamataki T (1995) Protective effects of Kampo medicine and baicaline against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn J Cancer Res 86:978

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Thoracic Diseases, Tochigi Cancer Center, 4-9-13 Yonan, Utsunomiya, 320, Tochigi, Japan

    Kiyoshi Mori, Tetsuro Kondo, Yukari Kamiyama, Yasuhiko Kano & Keigo Tominaga

Authors
  1. Kiyoshi Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tetsuro Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yukari Kamiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yasuhiko Kano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Keigo Tominaga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kiyoshi Mori.

Additional information

This work was supported in part by a Grant-in Aid for Cancer Research from the Ministry of Health, Labour and Welfare, the Foundation for the Promotion of Cancer Research, and the Second Term Comprehensive 10-Year Strategy for Cancer Control.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mori, K., Kondo, T., Kamiyama, Y. et al. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 51, 403–406 (2003). https://doi.org/10.1007/s00280-003-0585-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-003-0585-0

Keywords

Search

Navigation